COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

S. Panchawagh; N. Ravichandran; B. Barman; A. Nune; M. Javaid; A. E. Gracia-Ramos; J. Day; M. Joshi; M. Kuwana; S. Saha; A. R. Pande; C. V. Caballero-Uribe; T. Velikova; I. Parodis; J. Knitza; E. Kadam; A. L. Tan; S. K. Shinjo; H. Boro; P. Sen; J. Day; E. Nikiphorou; N. Ziade; M. Milchert; L. Cavagna; Y. M. Chen; A. Makol; V. Agarwal; A. Patel; J. D. Pauling; C. Wincup; E. A. Z. Tehozol; J. R. Serrano; La Torre I. G. -D.; I. J. Colunga-Pedraza; J. Merayo-Chalico; O. C. Chibuzo; W. Katchamart; P. A. Goo; R. Shumnalieva; L. S. Hoff; Kibbi L. El; H. Halabi; B. Vaidya; S. S. Shaharir; A. T. M. T. Hasan; D. Dey; C. E. T. Gutierrez; J. B. Lilleker; B. Salim; T. Gheita; O. Distler; M. A. Saavedra; S. Kardes; L. Andreoli; D. Lini; K. Schreiber; M. N. Vince; Y. P. Singh; R. Ranjan; A. Jain; S. C. Pandya; R. K. Pilania; A. Sharma; M. M. M; V. Gupta; C. G. Kavadichanda; P. S. Patro; S. Ajmani; S. Phatak; R. P. Goswami; A. C. Chowdhury; A. J. Mathew; P. Shenoy; A. Asranna; K. T. Bommakanti; A. Shukla; A. R. Pande; K. Chandwar; A. Ghodke; Z. Z. Fazal; D. U. Cansu; R. Yildirim; A. Y. Gasparyan; Papa N. Del; G. Sambataro; A. Fabiola; M. Govoni; S. Parisi; E. B. Bocci; G. D. Sebastiani; E. Fusaro; M. Sebastiani; L. Quartuccio; F. Franceschini; Pier Paolo SAINAGHI; G. Orsolini; Angelis R. De; M. G. Danielli; V. Venerito; S. Grignaschi; A. Giollo; A. Alluno; F. Ioannone; M. Fornaro; L. S. Traboco; S. A. K. Wibowo; J. Loarce-Martos; S. Prieto-Gonzalez; R. A. Gonzalez; A. Yoshida; R. Nakashima; S. Sato; N. Kimura; Y. Kaneko; T. Gono; S. Tomaras; F. N. Proft; Holzer M. -T.; M. A. Gromova; O. Aharonov; Z. Griger; I. Hmamouchi; bouchti I. El; Z. Baba; M. Giannini; F. Maurier; J. Campagne; A. Meyer; D. Langguth; V. Limaye; M. Needham; N. Srivastav; M. Hudson; O. Landon-Cardinal; W. G. R. Zuleta; A. Arbelaez; J. Cajas; J. A. P. Silva; J. E. Fonseca; O. Zimba; D. Bohdana; U. Ima-Edomwonyi; I. Dedeke; E. Airenakho; N. H. Madu; A. Yerima; H. Olaosebikan; B. A; O. D. Koussougbo; E. Palalane; H. So; M. F. Ugarte-Gil; L. Chinchay; J. P. Bernaola; V. Pimentel; H. M. Fathi; R. H. A. Mohammed; G. Harifi; Y. Fuentes-Silva; K. Cabriza; J. Losanto; N. Colaman; A. Cachafeiro-Vilar; G. G. Bautista; E. J. G. Ho; R. Gonzalez; L. S. Nunez; C. V. M; J. T. Baez; H. Alonzo; C. B. S. Pastelin; R. G. Salinas; A. Q. Obiols; N. Chavez; A. B. Ordonez; A. R. Llerena; R. Sierra-Zorita; D. Arrieta; E. R. Hidalgo; R. Saenz; M I. Escalante; W. Calapaqui; I. Quezada; G. Arredondo; R. Aggarwal; V. Agarwal; T. Chatterjee; L. Gupta

doi:10.1007/s00296-023-05496-y

COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

S. Panchawagh, N. Ravichandran, B. Barman, A. Nune, M. Javaid, A. E. Gracia-Ramos, J. Day, M. Joshi, M. Kuwana, S. Saha, A. R. Pande, C. V. Caballero-Uribe, T. Velikova, I. Parodis, J. Knitza, E. Kadam, A. L. Tan, S. K. Shinjo, H. Boro, P. SenJ. Day, E. Nikiphorou, N. Ziade, M. Milchert, L. Cavagna, Y. M. Chen, A. Makol, V. Agarwal, A. Patel, J. D. Pauling, C. Wincup, E. A. Z. Tehozol, J. R. Serrano, La Torre I. G. -D., I. J. Colunga-Pedraza, J. Merayo-Chalico, O. C. Chibuzo, W. Katchamart, P. A. Goo, R. Shumnalieva, L. S. Hoff, Kibbi L. El, H. Halabi, B. Vaidya, S. S. Shaharir, A. T. M. T. Hasan, D. Dey, C. E. T. Gutierrez, J. B. Lilleker, B. Salim, T. Gheita, O. Distler, M. A. Saavedra, S. Kardes, L. Andreoli, D. Lini, K. Schreiber, M. N. Vince, Y. P. Singh, R. Ranjan, A. Jain, S. C. Pandya, R. K. Pilania, A. Sharma, M. M. M, V. Gupta, C. G. Kavadichanda, P. S. Patro, S. Ajmani, S. Phatak, R. P. Goswami, A. C. Chowdhury, A. J. Mathew, P. Shenoy, A. Asranna, K. T. Bommakanti, A. Shukla, A. R. Pande, K. Chandwar, A. Ghodke, Z. Z. Fazal, D. U. Cansu, R. Yildirim, A. Y. Gasparyan, Papa N. Del, G. Sambataro, A. Fabiola, M. Govoni, S. Parisi, E. B. Bocci, G. D. Sebastiani, E. Fusaro, M. Sebastiani, L. Quartuccio, F. Franceschini, Pier Paolo SAINAGHI, G. Orsolini, Angelis R. De, M. G. Danielli, V. Venerito, S. Grignaschi, A. Giollo, A. Alluno, F. Ioannone, M. Fornaro, L. S. Traboco, S. A. K. Wibowo, J. Loarce-Martos, S. Prieto-Gonzalez, R. A. Gonzalez, A. Yoshida, R. Nakashima, S. Sato, N. Kimura, Y. Kaneko, T. Gono, S. Tomaras, F. N. Proft, Holzer M. -T., M. A. Gromova, O. Aharonov, Z. Griger, I. Hmamouchi, bouchti I. El, Z. Baba, M. Giannini, F. Maurier, J. Campagne, A. Meyer, D. Langguth, V. Limaye, M. Needham, N. Srivastav, M. Hudson, O. Landon-Cardinal, W. G. R. Zuleta, A. Arbelaez, J. Cajas, J. A. P. Silva, J. E. Fonseca, O. Zimba, D. Bohdana, U. Ima-Edomwonyi, I. Dedeke, E. Airenakho, N. H. Madu, A. Yerima, H. Olaosebikan, B. A, O. D. Koussougbo, E. Palalane, H. So, M. F. Ugarte-Gil, L. Chinchay, J. P. Bernaola, V. Pimentel, H. M. Fathi, R. H. A. Mohammed, G. Harifi, Y. Fuentes-Silva, K. Cabriza, J. Losanto, N. Colaman, A. Cachafeiro-Vilar, G. G. Bautista, E. J. G. Ho, R. Gonzalez, L. S. Nunez, C. V. M, J. T. Baez, H. Alonzo, C. B. S. Pastelin, R. G. Salinas, A. Q. Obiols, N. Chavez, A. B. Ordonez, A. R. Llerena, R. Sierra-Zorita, D. Arrieta, E. R. Hidalgo, R. Saenz, M I. Escalante, W. Calapaqui, I. Quezada, G. Arredondo, R. Aggarwal, V. Agarwal, T. Chatterjee, L. Gupta

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.

Lingua originale	Inglese
pagine (da-a)	73-80
Numero di pagine	8
Rivista	Rheumatology International
Volume	44
Numero di pubblicazione	1
DOI	https://doi.org/10.1007/s00296-023-05496-y
Stato di pubblicazione	Pubblicato - 2024

Keywords

Breakthrough infections
COVID-19
Survey
Type 1 diabetes mellitus
Vaccine

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1007/s00296-023-05496-y

https://hdl.handle.net/11579/169542

Altri file e collegamenti

handle

Cita questo

Panchawagh, S., Ravichandran, N., Barman, B., Nune, A., Javaid, M., Gracia-Ramos, A. E., Day, J., Joshi, M., Kuwana, M., Saha, S., Pande, A. R., Caballero-Uribe, C. V., Velikova, T., Parodis, I., Knitza, J., Kadam, E., Tan, A. L., Shinjo, S. K., Boro, H., ... Gupta, L. (2024). COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group. Rheumatology International, 44(1), 73-80. https://doi.org/10.1007/s00296-023-05496-y

@article{9f233d610ddb4a05804955d2899c1166,

title = "COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group",

abstract = "To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16\%) T1DM patients had one BI and 2 (2\%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.",

keywords = "Breakthrough infections, COVID-19, Survey, Type 1 diabetes mellitus, Vaccine, Breakthrough infections, COVID-19, Survey, Type 1 diabetes mellitus, Vaccine",

author = "S. Panchawagh and N. Ravichandran and B. Barman and A. Nune and M. Javaid and Gracia-Ramos, \{A. E.\} and J. Day and M. Joshi and M. Kuwana and S. Saha and Pande, \{A. R.\} and Caballero-Uribe, \{C. V.\} and T. Velikova and I. Parodis and J. Knitza and E. Kadam and Tan, \{A. L.\} and Shinjo, \{S. K.\} and H. Boro and P. Sen and J. Day and E. Nikiphorou and N. Ziade and M. Milchert and L. Cavagna and Chen, \{Y. M.\} and A. Makol and V. Agarwal and A. Patel and Pauling, \{J. D.\} and C. Wincup and Tehozol, \{E. A. Z.\} and Serrano, \{J. R.\} and -D., \{La Torre I. G.\} and Colunga-Pedraza, \{I. J.\} and J. Merayo-Chalico and Chibuzo, \{O. C.\} and W. Katchamart and Goo, \{P. A.\} and R. Shumnalieva and Hoff, \{L. S.\} and El, \{Kibbi L.\} and H. Halabi and B. Vaidya and Shaharir, \{S. S.\} and Hasan, \{A. T. M. T.\} and D. Dey and Gutierrez, \{C. E. T.\} and Lilleker, \{J. B.\} and B. Salim and T. Gheita and O. Distler and Saavedra, \{M. A.\} and S. Kardes and L. Andreoli and D. Lini and K. Schreiber and Vince, \{M. N.\} and Singh, \{Y. P.\} and R. Ranjan and A. Jain and Pandya, \{S. C.\} and Pilania, \{R. K.\} and A. Sharma and M, \{M. M.\} and V. Gupta and Kavadichanda, \{C. G.\} and Patro, \{P. S.\} and S. Ajmani and S. Phatak and Goswami, \{R. P.\} and Chowdhury, \{A. C.\} and Mathew, \{A. J.\} and P. Shenoy and A. Asranna and Bommakanti, \{K. T.\} and A. Shukla and Pande, \{A. R.\} and K. Chandwar and A. Ghodke and Fazal, \{Z. Z.\} and Cansu, \{D. U.\} and R. Yildirim and Gasparyan, \{A. Y.\} and Del, \{Papa N.\} and G. Sambataro and A. Fabiola and M. Govoni and S. Parisi and Bocci, \{E. B.\} and Sebastiani, \{G. D.\} and E. Fusaro and M. Sebastiani and L. Quartuccio and F. Franceschini and SAINAGHI, \{Pier Paolo\} and G. Orsolini and De, \{Angelis R.\} and Danielli, \{M. G.\} and V. Venerito and S. Grignaschi and A. Giollo and A. Alluno and F. Ioannone and M. Fornaro and Traboco, \{L. S.\} and Wibowo, \{S. A. K.\} and J. Loarce-Martos and S. Prieto-Gonzalez and Gonzalez, \{R. A.\} and A. Yoshida and R. Nakashima and S. Sato and N. Kimura and Y. Kaneko and T. Gono and S. Tomaras and Proft, \{F. N.\} and -T., \{Holzer M.\} and Gromova, \{M. A.\} and O. Aharonov and Z. Griger and I. Hmamouchi and El, \{bouchti I.\} and Z. Baba and M. Giannini and F. Maurier and J. Campagne and A. Meyer and D. Langguth and V. Limaye and M. Needham and N. Srivastav and M. Hudson and O. Landon-Cardinal and Zuleta, \{W. G. R.\} and A. Arbelaez and J. Cajas and Silva, \{J. A. P.\} and Fonseca, \{J. E.\} and O. Zimba and D. Bohdana and U. Ima-Edomwonyi and I. Dedeke and E. Airenakho and Madu, \{N. H.\} and A. Yerima and H. Olaosebikan and B. A and Koussougbo, \{O. D.\} and E. Palalane and H. So and Ugarte-Gil, \{M. F.\} and L. Chinchay and Bernaola, \{J. P.\} and V. Pimentel and Fathi, \{H. M.\} and Mohammed, \{R. H. A.\} and G. Harifi and Y. Fuentes-Silva and K. Cabriza and J. Losanto and N. Colaman and A. Cachafeiro-Vilar and Bautista, \{G. G.\} and Ho, \{E. J. G.\} and R. Gonzalez and Nunez, \{L. S.\} and M, \{C. V.\} and Baez, \{J. T.\} and H. Alonzo and Pastelin, \{C. B. S.\} and Salinas, \{R. G.\} and Obiols, \{A. Q.\} and N. Chavez and Ordonez, \{A. B.\} and Llerena, \{A. R.\} and R. Sierra-Zorita and D. Arrieta and Hidalgo, \{E. R.\} and R. Saenz and Escalante, \{M I.\} and W. Calapaqui and I. Quezada and G. Arredondo and R. Aggarwal and V. Agarwal and T. Chatterjee and L. Gupta",

year = "2024",

doi = "10.1007/s00296-023-05496-y",

language = "English",

volume = "44",

pages = "73--80",

journal = "Rheumatology International",

issn = "1437-160X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

Panchawagh, S, Ravichandran, N, Barman, B, Nune, A, Javaid, M, Gracia-Ramos, AE, Day, J, Joshi, M, Kuwana, M, Saha, S, Pande, AR, Caballero-Uribe, CV, Velikova, T, Parodis, I, Knitza, J, Kadam, E, Tan, AL, Shinjo, SK, Boro, H, Sen, P, Day, J, Nikiphorou, E, Ziade, N, Milchert, M, Cavagna, L, Chen, YM, Makol, A, Agarwal, V, Patel, A, Pauling, JD, Wincup, C, Tehozol, EAZ, Serrano, JR, -D., LTIG, Colunga-Pedraza, IJ, Merayo-Chalico, J, Chibuzo, OC, Katchamart, W, Goo, PA, Shumnalieva, R, Hoff, LS, El, KL, Halabi, H, Vaidya, B, Shaharir, SS, Hasan, ATMT, Dey, D, Gutierrez, CET, Lilleker, JB, Salim, B, Gheita, T, Distler, O, Saavedra, MA, Kardes, S, Andreoli, L, Lini, D, Schreiber, K, Vince, MN, Singh, YP, Ranjan, R, Jain, A, Pandya, SC, Pilania, RK, Sharma, A, M, MM, Gupta, V, Kavadichanda, CG, Patro, PS, Ajmani, S, Phatak, S, Goswami, RP, Chowdhury, AC, Mathew, AJ, Shenoy, P, Asranna, A, Bommakanti, KT, Shukla, A, Pande, AR, Chandwar, K, Ghodke, A, Fazal, ZZ, Cansu, DU, Yildirim, R, Gasparyan, AY, Del, PN, Sambataro, G, Fabiola, A, Govoni, M, Parisi, S, Bocci, EB, Sebastiani, GD, Fusaro, E, Sebastiani, M, Quartuccio, L, Franceschini, F, SAINAGHI, PP, Orsolini, G, De, AR, Danielli, MG, Venerito, V, Grignaschi, S, Giollo, A, Alluno, A, Ioannone, F, Fornaro, M, Traboco, LS, Wibowo, SAK, Loarce-Martos, J, Prieto-Gonzalez, S, Gonzalez, RA, Yoshida, A, Nakashima, R, Sato, S, Kimura, N, Kaneko, Y, Gono, T, Tomaras, S, Proft, FN, -T., HM, Gromova, MA, Aharonov, O, Griger, Z, Hmamouchi, I, El, BI, Baba, Z, Giannini, M, Maurier, F, Campagne, J, Meyer, A, Langguth, D, Limaye, V, Needham, M, Srivastav, N, Hudson, M, Landon-Cardinal, O, Zuleta, WGR, Arbelaez, A, Cajas, J, Silva, JAP, Fonseca, JE, Zimba, O, Bohdana, D, Ima-Edomwonyi, U, Dedeke, I, Airenakho, E, Madu, NH, Yerima, A, Olaosebikan, H, A, B, Koussougbo, OD, Palalane, E, So, H, Ugarte-Gil, MF, Chinchay, L, Bernaola, JP, Pimentel, V, Fathi, HM, Mohammed, RHA, Harifi, G, Fuentes-Silva, Y, Cabriza, K, Losanto, J, Colaman, N, Cachafeiro-Vilar, A, Bautista, GG, Ho, EJG, Gonzalez, R, Nunez, LS, M, CV, Baez, JT, Alonzo, H, Pastelin, CBS, Salinas, RG, Obiols, AQ, Chavez, N, Ordonez, AB, Llerena, AR, Sierra-Zorita, R, Arrieta, D, Hidalgo, ER, Saenz, R, Escalante, MI, Calapaqui, W, Quezada, I, Arredondo, G, Aggarwal, R, Agarwal, V, Chatterjee, T & Gupta, L 2024, 'COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group', Rheumatology International, vol. 44, n. 1, pagg. 73-80. https://doi.org/10.1007/s00296-023-05496-y

TY - JOUR

T1 - COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

AU - Panchawagh, S.

AU - Ravichandran, N.

AU - Barman, B.

AU - Nune, A.

AU - Javaid, M.

AU - Gracia-Ramos, A. E.

AU - Day, J.

AU - Joshi, M.

AU - Kuwana, M.

AU - Saha, S.

AU - Pande, A. R.

AU - Caballero-Uribe, C. V.

AU - Velikova, T.

AU - Parodis, I.

AU - Knitza, J.

AU - Kadam, E.

AU - Tan, A. L.

AU - Shinjo, S. K.

AU - Boro, H.

AU - Sen, P.

AU - Day, J.

AU - Nikiphorou, E.

AU - Ziade, N.

AU - Milchert, M.

AU - Cavagna, L.

AU - Chen, Y. M.

AU - Makol, A.

AU - Agarwal, V.

AU - Patel, A.

AU - Pauling, J. D.

AU - Wincup, C.

AU - Tehozol, E. A. Z.

AU - Serrano, J. R.

AU - -D., La Torre I. G.

AU - Colunga-Pedraza, I. J.

AU - Merayo-Chalico, J.

AU - Chibuzo, O. C.

AU - Katchamart, W.

AU - Goo, P. A.

AU - Shumnalieva, R.

AU - Hoff, L. S.

AU - El, Kibbi L.

AU - Halabi, H.

AU - Vaidya, B.

AU - Shaharir, S. S.

AU - Hasan, A. T. M. T.

AU - Dey, D.

AU - Gutierrez, C. E. T.

AU - Lilleker, J. B.

AU - Salim, B.

AU - Gheita, T.

AU - Distler, O.

AU - Saavedra, M. A.

AU - Kardes, S.

AU - Andreoli, L.

AU - Lini, D.

AU - Schreiber, K.

AU - Vince, M. N.

AU - Singh, Y. P.

AU - Ranjan, R.

AU - Jain, A.

AU - Pandya, S. C.

AU - Pilania, R. K.

AU - Sharma, A.

AU - M, M. M.

AU - Gupta, V.

AU - Kavadichanda, C. G.

AU - Patro, P. S.

AU - Ajmani, S.

AU - Phatak, S.

AU - Goswami, R. P.

AU - Chowdhury, A. C.

AU - Mathew, A. J.

AU - Shenoy, P.

AU - Asranna, A.

AU - Bommakanti, K. T.

AU - Shukla, A.

AU - Pande, A. R.

AU - Chandwar, K.

AU - Ghodke, A.

AU - Fazal, Z. Z.

AU - Cansu, D. U.

AU - Yildirim, R.

AU - Gasparyan, A. Y.

AU - Del, Papa N.

AU - Sambataro, G.

AU - Fabiola, A.

AU - Govoni, M.

AU - Parisi, S.

AU - Bocci, E. B.

AU - Sebastiani, G. D.

AU - Fusaro, E.

AU - Sebastiani, M.

AU - Quartuccio, L.

AU - Franceschini, F.

AU - SAINAGHI, Pier Paolo

AU - Orsolini, G.

AU - De, Angelis R.

AU - Danielli, M. G.

AU - Venerito, V.

AU - Grignaschi, S.

AU - Giollo, A.

AU - Alluno, A.

AU - Ioannone, F.

AU - Fornaro, M.

AU - Traboco, L. S.

AU - Wibowo, S. A. K.

AU - Loarce-Martos, J.

AU - Prieto-Gonzalez, S.

AU - Gonzalez, R. A.

AU - Yoshida, A.

AU - Nakashima, R.

AU - Sato, S.

AU - Kimura, N.

AU - Kaneko, Y.

AU - Gono, T.

AU - Tomaras, S.

AU - Proft, F. N.

AU - -T., Holzer M.

AU - Gromova, M. A.

AU - Aharonov, O.

AU - Griger, Z.

AU - Hmamouchi, I.

AU - El, bouchti I.

AU - Baba, Z.

AU - Giannini, M.

AU - Maurier, F.

AU - Campagne, J.

AU - Meyer, A.

AU - Langguth, D.

AU - Limaye, V.

AU - Needham, M.

AU - Srivastav, N.

AU - Hudson, M.

AU - Landon-Cardinal, O.

AU - Zuleta, W. G. R.

AU - Arbelaez, A.

AU - Cajas, J.

AU - Silva, J. A. P.

AU - Fonseca, J. E.

AU - Zimba, O.

AU - Bohdana, D.

AU - Ima-Edomwonyi, U.

AU - Dedeke, I.

AU - Airenakho, E.

AU - Madu, N. H.

AU - Yerima, A.

AU - Olaosebikan, H.

AU - A, B.

AU - Koussougbo, O. D.

AU - Palalane, E.

AU - So, H.

AU - Ugarte-Gil, M. F.

AU - Chinchay, L.

AU - Bernaola, J. P.

AU - Pimentel, V.

AU - Fathi, H. M.

AU - Mohammed, R. H. A.

AU - Harifi, G.

AU - Fuentes-Silva, Y.

AU - Cabriza, K.

AU - Losanto, J.

AU - Colaman, N.

AU - Cachafeiro-Vilar, A.

AU - Bautista, G. G.

AU - Ho, E. J. G.

AU - Gonzalez, R.

AU - Nunez, L. S.

AU - M, C. V.

AU - Baez, J. T.

AU - Alonzo, H.

AU - Pastelin, C. B. S.

AU - Salinas, R. G.

AU - Obiols, A. Q.

AU - Chavez, N.

AU - Ordonez, A. B.

AU - Llerena, A. R.

AU - Sierra-Zorita, R.

AU - Arrieta, D.

AU - Hidalgo, E. R.

AU - Saenz, R.

AU - Escalante, M I.

AU - Calapaqui, W.

AU - Quezada, I.

AU - Arredondo, G.

AU - Aggarwal, R.

AU - Agarwal, V.

AU - Chatterjee, T.

AU - Gupta, L.

PY - 2024

Y1 - 2024

N2 - To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.

AB - To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.

KW - Breakthrough infections

KW - COVID-19

KW - Survey

KW - Type 1 diabetes mellitus

KW - Vaccine

KW - Breakthrough infections

KW - COVID-19

KW - Survey

KW - Type 1 diabetes mellitus

KW - Vaccine

UR - https://iris.uniupo.it/handle/11579/169542

U2 - 10.1007/s00296-023-05496-y

DO - 10.1007/s00296-023-05496-y

M3 - Article

SN - 1437-160X

VL - 44

SP - 73

EP - 80

JO - Rheumatology International

JF - Rheumatology International

IS - 1

ER -

COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo